Recombinant Proteins Market
Recombinant Proteins Market by Product (Growth Factors, Chemokines, Membrane Proteins, Receptors), Host Cell (Mammalian, Insect, Yeast), Application (Drug Discovery, Development [Biologics, CGT, Vaccines], Research, Production)- Global Forecast to 2031
RECOMBINANT PROTEINS MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global recombinant proteins market is projected to grow from USD 2.63 billion in 2026 to USD 3.90 billion by 2031, at a CAGR of 8.2% during the forecast period. The market was valued at USD 2.47 billion in 2025. Market growth is driven by the expanding pipeline of recombinant therapeutics, increasing demand for biologics, and growing applications in drug discovery, vaccine development, diagnostics, and cell and gene therapy. Advances in protein engineering, mammalian expression systems, and purification technologies are improving protein yield, stability, biological activity, and manufacturing scalability. Increasing use of recombinant growth factors, chemokines, enzymes, receptors, and immune-related proteins across pharmaceutical, biotechnology, and research settings is accelerating market adoption. Additionally, rising investments in biopharmaceutical manufacturing and growing demand for high-purity, consistent, and application-specific recombinant proteins are supporting market expansion.
KEY TAKEAWAYS
-
MARKET SNAPSHOT:
Base Year Market Size (2025): USD 2.47 Billion
Current Market Size (2026): USD 2.63 Billion
Forecast Market Size (2031): USD 3.90 Billion
CAGR (2026–2031): 8.2% -
SEGMENT LEADERSHIP:
Regional Leader: North America accounted for the largest share of 46.3% of the recombinant proteins market in 2025.
Product Leader: Growth factors & chemokines accounted for the largest share of 34.9% in 2025.
Expression System Leader: Bacterial cells accounted for the largest share of 38.1% in 2025.
Application Leader: Drug discovery & development accounted for the largest share of 37.2% in 2025.
End User Leader: Pharmaceutical & biopharmaceutical companies accounted for the largest share of 46.3% in 2025. -
MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), and Bio-Techne (US) were identified as some of the star players in the recombinant proteins market, given their strong market share and product footprint.
Companies such as RayBiotech, Inc. (US), Icosagen (South Korea), and Qkine Ltd. (China), among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.
The recombinant proteins market is growing due to the expanding pipeline of recombinant therapeutics, increasing demand for biologics, and wider applications in drug discovery, vaccine development, diagnostics, and cell and gene therapy. Advances in protein engineering, expression systems, and purification technologies are improving protein yield, stability, and biological activity, supporting adoption across research and biopharmaceutical manufacturing.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The recombinant proteins market is evolving through advances in protein engineering, expression systems, and purification technologies that improve protein yield, stability, biological activity, and consistency. Increasing adoption of engineered recombinant proteins, including growth factors, chemokines, enzymes, receptors, and immune-related proteins, is supporting applications across drug discovery, biologics development, vaccine production, diagnostics, and cell and gene therapy. Advances in mammalian expression systems, optimized cell-line development, and scalable bioprocessing are enabling more efficient production of complex therapeutic proteins. Additionally, growing demand for high-purity, application-specific proteins and ready-to-use formulations is supporting broader adoption across pharmaceutical and biotechnology companies, academic and research institutes, and contract research organizations. These developments are strengthening protein production capabilities, supporting biopharmaceutical manufacturing, and creating opportunities for the development of novel recombinant therapeutics.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Growing pipeline for recombinant therapeutic proteins

-
Shift toward mammalian expression systems
Level
-
High lot-to-lot variability and inconsistency in off-the-shelf recombinant proteins
-
High costs associated with premium recombinant proteins expressed in mammalian cells
Level
-
Emergence of ready-to-use liquid formulations for integration into automated high-throughput workflows
-
Development of bio-engineered, heat-stable protein variants for continuous cell lines & cell culture
Level
-
Advent of non-protein mimics and alternative modalities
-
Rising supply chain complexities
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Growing pipeline for recombinant therapeutic proteins
The expanding pipeline of recombinant therapeutics is driving demand across drug discovery and clinical development. Increasing development of proteins for cancer, autoimmune disorders, and genetic diseases is supporting their use in target validation, functional assays, and therapeutic development. Advances in protein engineering and expression technologies are further enabling the development of complex biologics and engineered proteins.
Restraint: High lot-to-lot variability and inconsistency in off-the-shelf recombinant proteins
Variability in protein purity, biological activity, folding, and post-translational modifications can affect experimental reproducibility and biopharmaceutical workflows. Differences between batches and expression systems may influence protein performance in drug discovery, cell culture, and functional assays, increasing validation requirements, development costs, and research timelines.
Opportunity: Emergence of ready-to-use liquid formulations for integration into automated high-throughput workflows
Ready-to-use liquid recombinant proteins can improve workflow efficiency, reduce preparation time, and support automated high-throughput screening. Standardized formulations simplify handling and minimize preparation-related variability. Growing automation in drug discovery, biologics development, and cell culture creates opportunities for suppliers offering stable, application-specific proteins in convenient formats.
Challenge: Advent of non-protein mimics and alternative modalities
Recombinant proteins face competition from alternative modalities, including small molecules, peptides, and nucleic acid-based therapies. Depending on the application, these alternatives may offer advantages in delivery, stability, manufacturing, or cost. Recombinant protein developers must demonstrate strong biological activity, safety, efficacy, and commercial value to remain competitive.
RECOMBINANT PROTEINS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Recombinant cytokines and growth factors from its Gibco, Invitrogen, and PeproTech brands are used in cell culture, drug discovery, immunology research, stem cell expansion, and cell therapy manufacturing. Its GMP-grade proteins support the production of cell-based therapies. | Supports reproducible cell culture and immune-cell expansion | Enables research-to-manufacturing workflows | Supports clinical manufacturing requirements through GMP-grade proteins. |
|
|
Merck provides recombinant protein expression and process-development technologies for biopharmaceutical applications. Its CHOZN expression platform and associated process-development services support the development and scale-up of recombinant proteins and other biologics. | Supports high-producing cell-line development | Facilitates process optimization and scale-up | Helps improve manufacturing productivity and consistency. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The recombinant proteins market ecosystem comprises raw material providers, technology and equipment manufacturers, service providers, end users, and regulatory authorities. Raw material suppliers, including Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), and Danaher Corporation (US), provide culture media, expression reagents, and purification materials. Product providers, including Thermo Fisher Scientific Inc. (US), Bio-Techne (US), GenScript (China), Sino Biological, Inc. (China), and Abnova Corporation (Taiwan), supply recombinant proteins and custom expression services for drug discovery, biologics development, and research. End users, including pharmaceutical and biopharmaceutical companies, biotechnology companies, CROs, and academic and research institutes, use recombinant proteins in therapeutic development, vaccine research, diagnostics, and biotechnology research. Regulatory authorities, including the US FDA, EMA, and CDSCO, establish quality, safety, and manufacturing requirements, particularly for recombinant proteins intended for therapeutic applications.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Recombinant Proteins Market, By Product
In 2025, the growth factors & chemokines segment dominated the recombinant proteins market, driven by their extensive use in cell culture, cell signaling, drug discovery, and therapeutic development. Increasing demand for cytokines, chemokines, and growth factors in stem cell research, cancer studies, and biologics development supports segment growth. Advances in protein engineering and the growing need for high-purity, application-specific proteins further strengthen demand.
Recombinant Proteins Market, By Host Cell
In 2025, the bacterial cells segment dominated the recombinant proteins market, owing to their rapid growth, cost-effective cultivation, and ease of genetic manipulation. These systems, particularly E. coli, are widely used to produce recombinant proteins for research, enzyme production, and selected therapeutic applications. Established production processes, scalability, and lower manufacturing costs compared with mammalian expression systems further support the adoption of bacterial cells.
Recombinant Proteins Market, By Application
In 2025, the drug discovery & development segment dominated the recombinant proteins market, supported by the growing use of recombinant proteins in target validation, functional assays, disease modeling, and drug screening. Pharmaceutical and biotechnology companies increasingly use these proteins to investigate biological pathways and assess potential drug candidates. Growing biologics pipelines and demand for reliable, high-quality research reagents further support adoption in drug discovery and development.
RECOMBINANT PROTEINS MARKET: COMPANY EVALUATION MATRIX
In the recombinant proteins market company evaluation matrix, Thermo Fisher Scientific Inc. (US) is positioned as a star player due to its broad portfolio of recombinant proteins, including growth factors, cytokines, chemokines, and other proteins offered through its Gibco, Invitrogen, and PeproTech brands. Its extensive product range, global distribution network, and support for drug discovery, cell culture, and biopharmaceutical development strengthen its competitive position. Sino Biological, Inc. (China) is considered an emerging leader in the recombinant proteins market. The company offers an extensive portfolio of recombinant proteins, including cytokines, growth factors, enzymes, and membrane proteins, alongside custom protein expression and production services. Its specialized protein expertise, expanding product portfolio, and support for drug discovery, antibody development, and biomedical research strengthen its position in the market.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Bio-Techne (US)
- Thermo Fisher Scientific Inc. (US)
- Merck KGaA (Germany)
- Danaher Corporation (US)
- Abnova Corporation (Taiwan)
- Bio-Rad Laboratories, Inc. (US)
- BPS Bioscience, Inc. (US)
- Sino Biological, Inc. (China)
- GenScript (China)
- Proteintech Group, Inc. (US)
- Miltenyi Biotec (Germany)
- Enzo Biochem Inc. (US)
- Revvity (US)
- Sartorius AG (Germany)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2026 (Value) | USD 2.63 Billion |
| Market Forecast in 2031 (Value) | USD 3.90 Billion |
| Growth Rate | CAGR of 8.2% from 2026-2031 |
| Years Considered | 2023-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East, Africa |
WHAT IS IN IT FOR YOU: RECOMBINANT PROTEINS MARKET REPORT CONTENT GUIDE

DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Rest of Europe Breakdown | Country-level market sizing and growth forecasts (Switzerland, Sweden, Turkey, the Netherlands, Norway, Poland, Portugal, Romania, Denmark, Estonia, Finland, the Czech Republic, Greece, Austria, Belgium, and Russia) | Provides granular country-level insights, enabling clients to prioritize high-growth markets |
| Company Evaluation |
|
Delivers visibility into competitors, helping clients identify partners, evaluate positioning, and detect market gaps for smarter collaboration, outsourcing, and strategic market entry decisions |
RECENT DEVELOPMENTS
- July 2026 : Merck opened a BioReliance testing facility in Darmstadt, Germany, to enhance access to drug substance and product release testing in Europe. The site supports biologics developers, including recombinant protein manufacturers, by providing GMP-compliant analytical and biosafety testing services closer to production.
- April 2026 : Miltenyi Biotec launched a research-grade recombinant human IL-18, a pro-inflammatory cytokine optimized for in vitro and in vivo studies. This product is designed for researchers focused on immune modulation, inflammation, and cell-based therapies, enhancing Miltenyi’s recombinant protein portfolio for research applications.
- September 2025 : Integrated DNA Technologies, a Danaher company, launched a research-grade recombinant enhancer protein aimed at improving the efficiency of CRISPR homology-directed repair. This protein enhances the CRISPR nuclease toolkit, facilitating the development of gene-editing workflows that utilize recombinant proteins for translational and clinical research.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global recombinant proteins market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.
Secondary Research
The secondary sources referred to for this research study include publications from government sources,such as the World Health Organization, The Antibody Society,Pharmaceutical Research and Manufacturers of America (PhRMA), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC),National Center for Biotechnology Information (NCBI), American Medical Association (AMA), RecombinantAntibody Network (RAN), National Cancer Institute (NCI), Association of Medical Laboratory Immunologists (AMLI), American Society of Clinical Oncology (ASCO), United States Food & Drug Administration (US FDA), American Association for Cancer Research (AACR), Biomolecular Interaction Network Database, European Medicines Agency (EMA), British Society for Immunology (BSI), and the Institute for Molecular Medicine, corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, professional associations, and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate & validate the total size of the recombinant proteins market. These methods were also used extensively to estimate the size of various market segments.

Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data were triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
Recombinant proteins are manipulated proteins generated by recombinant DNA technology that modifies gene sequences. These are formed by transfecting foreign genes into a host cell. Recombinant proteins are primarily used to produce antibodies and enzymes for disease treatment, pharmaceutical products, protein-based polymers for drug delivery, and various other research & diagnostic uses. This market includes recombinant protein products, including growth factors, cytokines, recombinant enzymes, structural proteins, and membrane proteins.
Key Stakeholders
- Pharmaceutical & Biopharmaceutical Companies
- Biotechnology Companies
- Life Sciences Companies
- Academic Research Institutes
- Government Institutes
- Private Research Firms
- Contract Research Organizations (CROs)
- Third-party Suppliers, Direct Suppliers, Distributors, and Channel Partners
- Venture Capitalists and Investors
- Market Research and Consulting Firms
Report Objectives
- To define, describe, and forecast the recombinant proteins market based on product, host cell, application, and end user
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall recombinant proteins market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the recombinant proteins market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the recombinant proteins market
- To benchmark players within the recombinant proteins market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:
Geographical Analysis
- Further breakdown of the Rest of Europe recombinant proteins market, by country
- Further breakdown of the Rest of Asia Pacific recombinant proteins market, by country
- Further breakdown of the Rest of Latin America recombinant proteins market, by country
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Recombinant Proteins Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationTESTIMONIALS
- China Recombinant Proteins Market
- Japan Recombinant Proteins Market
- India Recombinant Proteins Market
- South Korea Recombinant Proteins Market
- Brazil Recombinant Proteins Market
- Rest Of Europe Recombinant Proteins Market
- United Kingdom Recombinant Proteins Market
- Rest Of Asia Pacific Recombinant Proteins Market
- Rest Of Latin America Recombinant Proteins Market
- GCC Countries Recombinant Proteins Market
- Rest Of The Middle East Recombinant Proteins Market
- Canada Recombinant Proteins Market
- US Recombinant Proteins Market
- Germany Recombinant Proteins Market
- UK Recombinant Proteins Market
- France Recombinant Proteins Market
- Italy Recombinant Proteins Market
- Spain Recombinant Proteins Market
Growth opportunities and latent adjacency in Recombinant Proteins Market

Kahlill
May, 2022
What are the growth estimates for Recombinant protein market till 2026?.
James
May, 2022
What are the key factors hampering growth of the Recombinant protein market?.
Peggy
May, 2022
Interested in data of Recombinant Protein Market, Industry Share, Size, Growth and forecasts of 2027 - 2030.
John
Dec, 2022
How big is the recombinant proteins market?.